Trial Review

ANZCTR is currently experiencing a technical issue. Thank you for your patience while we work on it and apologies for any inconvenience caused.


Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements.
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00676143




Registration number
NCT00676143
Ethics application status
Date submitted
2/05/2008
Date registered
12/05/2008
Date last updated
10/06/2016

Titles & IDs
Public title
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
Scientific title
A Phase Iii, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Efficacy And Safety Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Mild To Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Carriers
Secondary ID [1] 0 0
B2521002
Secondary ID [2] 0 0
3133K1-3001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Alzheimer Disease 0 0
Condition category
Condition code
Neurological 0 0 0 0
Alzheimer's disease
Neurological 0 0 0 0
Dementias

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - bapineuzumab
Treatment: Drugs - placebo

Experimental: Bapineuzumab 0.5 mg/kg -

Placebo comparator: Placebo -


Treatment: Drugs: bapineuzumab
Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.

Treatment: Drugs: placebo
Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)/11 Subscale Total Score at Week 78
Assessment method [1] 0 0
The ADAS-Cog is a multi-item, objective measure of cognitive function. The scale evaluates memory, language, and praxis with items such as orientation, word recall, word recognition, object identification, comprehension, and the completion of simple tasks. Analysis of the ADAS-Cog for this study was based upon an 11 item score from the following items 1) word recall task, 2) naming objects and fingers, 3) following commands, 4) constructional praxis, 5) ideational praxis, 6) orientation, 7) word recognition, 8) remembering test instructions, 9) spoken language ability, 10) word finding difficulty in spontaneous speech, and 11) comprehension. This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced. The ADAS-Cog/11 ranged from 0 to 70 points, with higher scores indicating a greater degree of impairment. A negative change from baseline indicates a decrease in cognitive impairment.
Timepoint [1] 0 0
Baseline and 78 weeks
Primary outcome [2] 0 0
Change From Baseline in Disability Assessment for Dementia (DAD) Total Score at Week 78
Assessment method [2] 0 0
The DAD measures instrumental and basic activities of daily living in participants with Alzheimer's Disease (AD). The DAD is administered to the participants'caregiver in the form of an interview. This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced by the participant. This scale assesses a participants' ability to initiate, plan, and perform activities related to hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. Each item can be scored as 1 = yes, 0 = no, non applicable = NA. A total score is obtained by adding the rating for each question and converting this total score out of 100. Higher scores indicate better function; a positive change from baseline indicates an improvement.
Timepoint [2] 0 0
Baseline and 78 weeks
Secondary outcome [1] 0 0
Change From Baseline in Brain Amyloid Burden at Week 71
Assessment method [1] 0 0
Brain amyloid burden as imaged by 11C-Pittsburgh compound B (PIB) positron emission tomography (PET). The latter is a semi-quantitative measure of the extent of fibrillar amyloid in the brain. PIB PET measurements were made in cortical regions found to have the highest burden of fibrillar amyloid at autopsy in participants diagnosed as having Alzheimer's pathology, and also regions reported to have the highest average retention of PIB signal in previous PET studies enrolling participants with probable AD. This parameter reflects overall brain amyloid deposition as indexed by imaging. The change from baseline was measured as average standard uptake value ratio (SUVr) in prespecified regions of interest (ROI) assessed by PIB PET imaging in a subset of participants.
Timepoint [1] 0 0
Baseline and 71 weeks
Secondary outcome [2] 0 0
Change From Baseline in Cerebrospinal Fluid (CSF) Phospho-tau Levels at Week 71
Assessment method [2] 0 0
Biomarkers CSF phospho-tau is an indicator of neuronal injury and neurodegeneration. An elevation in levels of tau, as well as specific p-tau species, is thought to be a marker for progressive cellular degeneration in AD. Accordingly, a reduction from baseline in levels of CSF tau in participants who received bapineuzumab compared with participants who received placebo may be indicative of a reduction in neuronal loss in participants treated with bapineuzumab.
Timepoint [2] 0 0
Baseline and 71 Weeks
Secondary outcome [3] 0 0
Change From Baseline in Brain Volume, as Assessed by Magnetic Resonance Imaging Brain Boundary Shift Integral (MRI BBSI), at Week 71
Assessment method [3] 0 0
Cerebral atrophy correlates closely with the gradual cognitive decline in AD and can be visualized by MRI. The BBSI technique involves positional matching of serial 3-dimensional MRI brain images, such that brain MRI-image volumes were first registered and then subtracted from each other. Atrophy rates would generally be expected to be lower if the underlying disease was attenuated by effective treatment.
Timepoint [3] 0 0
Baseline and 71 Weeks
Secondary outcome [4] 0 0
Divergence of Effect on the ADAS-Cog/11 Total Scores From Week 39 to Week 78
Assessment method [4] 0 0
Treatment differences are estimated using least-squares (LS) means with factor levels weighted according to overall analysis population proportions. ADAS-Cog/11 total score range is 0 (least impairment) to 70 (most impairment); a negative treatment difference (bapineuzumab minus placebo) favors bapineuzumab. Within the MMRMs for ADAS-Cog/11 described for the primary analyses, linear contrasts were formed to test increasing trend of the differences between bapineuzumab and placebo from Week 39 (the 9-month visit) through Week 78 (the 18 -month visit) for each variable, which is equivalent to testing a positive slope of the differences between each bapineuzumab dose group and placebo from Week 39 through Week 78. Results are from a restricted maximum likelihood (REML)-based mixed model for MMRM.
Timepoint [4] 0 0
Week 39 to Week 78
Secondary outcome [5] 0 0
Divergence of Effect on the DAD Total Scores From Week 39 to Week 78
Assessment method [5] 0 0
Treatment differences are estimated using least-squares (LS) means with factor levels weighted according to overall analysis population proportions. DAD total score range is 0 to 100; a positive treatment difference (bapineuzumab minus placebo) favors bapineuzumab. Within the MMRMs for ADAS-Cog/11 described for the primary analyses, linear contrasts were formed to test increasing trend of the differences between bapineuzumab and placebo from Week 39 (the 9-month visit) through Week 78 (the 18 -month visit) for each variable, which is equivalent to testing a positive slope of the differences between each bapineuzumab dose group and placebo from Week 39 through Week 78. Results are from a restricted maximum likelihood (REML)-based mixed model for MMRM.
Timepoint [5] 0 0
Week 39 to Week 78
Secondary outcome [6] 0 0
Time to First Median Placebo Deterioration on ADAS-Cog/11 Total Score (European Union [EU] Analysis Plan)
Assessment method [6] 0 0
The time to first median placebo deterioration, defined as the first time a participant experienced an increase (worsening) from baseline in ADAS-Cog/11 total score greater than or equal to the median worsening observed at Week 78 in the placebo group. The Kaplan Meier estimate of median time to first median placebo deterioration was presented.
Timepoint [6] 0 0
Baseline and 78 Weeks
Secondary outcome [7] 0 0
Time to First Clinically Meaningful Deterioration on ADAS-Cog/11 Total Score (United States [US] Analysis Plan)
Assessment method [7] 0 0
The time to first clinically meaningful deterioration was defined as the first time a participant experienced an increase (worsening) from baseline in ADAS-Cog/11 total score of \>=7.
Timepoint [7] 0 0
Baseline and 78 Weeks
Secondary outcome [8] 0 0
Time to First Median Placebo Deterioration on DAD Total Score (EU Analysis Plan)
Assessment method [8] 0 0
The time to first median placebo deterioration was defined as the first time a participant experienced a decrease (worsening) in DAD total score greater than or equal to the median worsening at Week 78 in the placebo group.
Timepoint [8] 0 0
Baseline and 78 Weeks
Secondary outcome [9] 0 0
Time to First Clinically Meaningful Deterioration on DAD Total Score (US Analysis)
Assessment method [9] 0 0
The time to first clinically meaningful deterioration was defined as the first time a participant experienced a decrease (worsening) from baseline in DAD total score of \>=12.
Timepoint [9] 0 0
Baseline and 78 Weeks
Secondary outcome [10] 0 0
Change From Baseline in Dependence Scale Total Score at Week 78
Assessment method [10] 0 0
The Dependence Scale (DS) is a 13-item, caregiver-rated instrument for determining the amount of support required by a participant with AD. The DS total score ranges from 0 to 15, with higher scores indicating more need for assistance. The DS was administered as an interview to the caregiver at scheduled study visits.
Timepoint [10] 0 0
Baseline and 78 Weeks
Secondary outcome [11] 0 0
Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (EU Analysis Plan)
Assessment method [11] 0 0
Percentage of participants with worsening from baseline to Week 78 in ADAS-Cog/11 total score of =0, =3, and =7 points were reported. In order to calculate time to first median placebo deterioration in ADAS-Cog/11, the median change from baseline to Week 78 among the placebo participants of the mITT analysis population were determined. The median changes were used as the cutpoints for determining "deterioration" for Alzheimer's disease participants in the study. If the median change from baseline to Week 78 in the ADAS-Cog/11 total score among the placebo participants of the mITT Analysis Population is 7 points, then the first median placebo deterioration is the first time where there is a worsening on the ADAS-Cog/11 total score of 7 points or more and the worsening is confirmed by the ADAS-Cog/11 assessment at the next non-missing visit.
Timepoint [11] 0 0
Baseline and 78 Weeks
Secondary outcome [12] 0 0
Percentage of Responders for ADAS-Cog/11 Total Score at Week 78 (US Analysis Plan)
Assessment method [12] 0 0
Percentage of participants whose increase (worsening) from baseline to Week 78 in ADAS-Cog/11 total score was \<7.
Timepoint [12] 0 0
Baseline and 78 Weeks
Secondary outcome [13] 0 0
Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (EU Analysis Plan)
Assessment method [13] 0 0
Percentage of participants whose decrease (worsening) from baseline to Week 78 in DAD total score of = 0, = 6, and = 12 points. In order to calculate time to first median placebo deterioration in DAD, the median change from baseline to Week 78 among the placebo participants of the mITT analysis population were determined. The median changes were used as the cutpoints for determining "deterioration" for Alzheimer's disease participants in the study. If the median change from baseline to Week 78 in the DAD total score among the placebo participants of the mITT Analysis Population is 7 points, then the first median placebo deterioration is the first time where there is a worsening on the DAD total score of 7 points or more and the worsening is confirmed by the DAD assessment at the next non-missing visit.
Timepoint [13] 0 0
Baseline and 78 Weeks
Secondary outcome [14] 0 0
Percentage of Responders for DAD Total Score at Week 78 (US Analysis Plan)
Assessment method [14] 0 0
Percentage of participants whose decrease (worsening) from baseline to Week 78 in DAD total score was \<12.
Timepoint [14] 0 0
Baseline and 78 Weeks
Secondary outcome [15] 0 0
Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SOB) Total Score at Week 78
Assessment method [15] 0 0
The CDR-SOB is a global clinical staging instrument that sums 6 clinical ratings: 1) memory, 2) orientation, 3) judgment and problem solving, 4) involvement in community affairs, 5) home and hobbies, and 6) personal care based on the Clinical Dementia Rating Scale (CDR) interview. The CDR includes discussions with the participant and caregiver using a structured format. This scale had to be administered by a trained and certified global rater who did not have access to any information regarding adverse events experienced by the participant. CDR-SOB total score range is 0 (least impairment) to 18 (most impairment); a negative change from baseline indicates an improvement.
Timepoint [15] 0 0
Baseline and 78 Weeks

Eligibility
Key inclusion criteria
* Diagnosis of probable AD, with MMSE score of 16-26, and brain MRI consistent with the diagnosis of AD
* Concurrent use of cholinesterase inhibitor or memantine allowed, if stable.
* Caregiver will participate and be able to attend clinic visits with patient.
Minimum age
50 Years
Maximum age
88 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Significant neurological disease other than AD, or a major psychiatric disorder
* Contraindication to undergo brain MRI (e.g., pacemaker, CSF shunt, or foreign metal objects in the body)
* Woman of childbearing potential

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/01/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/11/2012
Sample size
Target
Accrual to date
Final
1100
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Recruitment hospital [1] 0 0
Gosford Hospital; Pharmacy Dept - Gosford
Recruitment hospital [2] 0 0
Gosford Hospital - Gosford
Recruitment hospital [3] 0 0
Hornsby Kuringai Hospital - Hornsby
Recruitment hospital [4] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [5] 0 0
The Queen Elizabeth Hospital - Woodville South
Recruitment hospital [6] 0 0
CDAMS Ballarat Base Hospital - Ballarat
Recruitment hospital [7] 0 0
Heidelberg Repatriation Hospital - West Heidelberg
Recruitment hospital [8] 0 0
Hollywood Hospital; Pharmacy Dept - Nedlands
Recruitment hospital [9] 0 0
McCusker Alzheimer's Research Foundation, Inc. - Nedlands
Recruitment postcode(s) [1] 0 0
2250 - Gosford
Recruitment postcode(s) [2] 0 0
2077 - Hornsby
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
5011 - Woodville South
Recruitment postcode(s) [5] 0 0
3353 - Ballarat
Recruitment postcode(s) [6] 0 0
3081 - West Heidelberg
Recruitment postcode(s) [7] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Mississippi
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
New Jersey
Country [17] 0 0
United States of America
State/province [17] 0 0
New York
Country [18] 0 0
United States of America
State/province [18] 0 0
North Carolina
Country [19] 0 0
United States of America
State/province [19] 0 0
Ohio
Country [20] 0 0
United States of America
State/province [20] 0 0
Oregon
Country [21] 0 0
United States of America
State/province [21] 0 0
Pennsylvania
Country [22] 0 0
United States of America
State/province [22] 0 0
Rhode Island
Country [23] 0 0
United States of America
State/province [23] 0 0
South Carolina
Country [24] 0 0
United States of America
State/province [24] 0 0
Texas
Country [25] 0 0
United States of America
State/province [25] 0 0
Vermont
Country [26] 0 0
United States of America
State/province [26] 0 0
Wisconsin
Country [27] 0 0
Argentina
State/province [27] 0 0
Buenos Aires
Country [28] 0 0
Argentina
State/province [28] 0 0
Cordoba
Country [29] 0 0
Austria
State/province [29] 0 0
Graz
Country [30] 0 0
Austria
State/province [30] 0 0
Klagenfurt
Country [31] 0 0
Austria
State/province [31] 0 0
Wien
Country [32] 0 0
Belgium
State/province [32] 0 0
Antwerpen
Country [33] 0 0
Belgium
State/province [33] 0 0
Brugge
Country [34] 0 0
Belgium
State/province [34] 0 0
Brussels
Country [35] 0 0
Belgium
State/province [35] 0 0
Edegem
Country [36] 0 0
Belgium
State/province [36] 0 0
Leuven
Country [37] 0 0
Belgium
State/province [37] 0 0
Roeselare
Country [38] 0 0
Chile
State/province [38] 0 0
Santiago
Country [39] 0 0
Croatia
State/province [39] 0 0
Zagreb
Country [40] 0 0
Finland
State/province [40] 0 0
Kuopio
Country [41] 0 0
Finland
State/province [41] 0 0
Turku
Country [42] 0 0
France
State/province [42] 0 0
Bordeaux Cedex
Country [43] 0 0
France
State/province [43] 0 0
Bron
Country [44] 0 0
France
State/province [44] 0 0
Caen
Country [45] 0 0
France
State/province [45] 0 0
Colmar
Country [46] 0 0
France
State/province [46] 0 0
Dijon
Country [47] 0 0
France
State/province [47] 0 0
Lille
Country [48] 0 0
France
State/province [48] 0 0
Marseille
Country [49] 0 0
France
State/province [49] 0 0
Montpellier
Country [50] 0 0
France
State/province [50] 0 0
Nantes - Saint Herblain
Country [51] 0 0
France
State/province [51] 0 0
Nice
Country [52] 0 0
France
State/province [52] 0 0
Paris
Country [53] 0 0
France
State/province [53] 0 0
Poitiers
Country [54] 0 0
France
State/province [54] 0 0
Reims
Country [55] 0 0
France
State/province [55] 0 0
Rennes Cedex
Country [56] 0 0
France
State/province [56] 0 0
Rouen
Country [57] 0 0
France
State/province [57] 0 0
Toulouse
Country [58] 0 0
Germany
State/province [58] 0 0
Berlin
Country [59] 0 0
Germany
State/province [59] 0 0
Bochum
Country [60] 0 0
Germany
State/province [60] 0 0
Dresden
Country [61] 0 0
Germany
State/province [61] 0 0
Freiburg
Country [62] 0 0
Germany
State/province [62] 0 0
Offenburg
Country [63] 0 0
Germany
State/province [63] 0 0
Ulm
Country [64] 0 0
Italy
State/province [64] 0 0
Ancona
Country [65] 0 0
Italy
State/province [65] 0 0
Brescia
Country [66] 0 0
Italy
State/province [66] 0 0
Catania
Country [67] 0 0
Italy
State/province [67] 0 0
Chieti
Country [68] 0 0
Italy
State/province [68] 0 0
Milano
Country [69] 0 0
Italy
State/province [69] 0 0
Monza
Country [70] 0 0
Italy
State/province [70] 0 0
Roma
Country [71] 0 0
Italy
State/province [71] 0 0
Siena
Country [72] 0 0
Japan
State/province [72] 0 0
Aichi,
Country [73] 0 0
Japan
State/province [73] 0 0
Tokyo
Country [74] 0 0
Japan
State/province [74] 0 0
Aichi
Country [75] 0 0
Japan
State/province [75] 0 0
Chiba
Country [76] 0 0
Japan
State/province [76] 0 0
Fukuoka
Country [77] 0 0
Japan
State/province [77] 0 0
Gunma
Country [78] 0 0
Japan
State/province [78] 0 0
Hiroshima
Country [79] 0 0
Japan
State/province [79] 0 0
Hyogo
Country [80] 0 0
Japan
State/province [80] 0 0
Iwate
Country [81] 0 0
Japan
State/province [81] 0 0
Kagawa
Country [82] 0 0
Japan
State/province [82] 0 0
Kanagawa
Country [83] 0 0
Japan
State/province [83] 0 0
Kyoto
Country [84] 0 0
Japan
State/province [84] 0 0
Nagano
Country [85] 0 0
Japan
State/province [85] 0 0
Niigata
Country [86] 0 0
Japan
State/province [86] 0 0
Okayama
Country [87] 0 0
Japan
State/province [87] 0 0
Osaka
Country [88] 0 0
Japan
State/province [88] 0 0
Shizuoka
Country [89] 0 0
Mexico
State/province [89] 0 0
Nuevo León
Country [90] 0 0
Mexico
State/province [90] 0 0
Aguascalientes
Country [91] 0 0
Netherlands
State/province [91] 0 0
Noord Brabant
Country [92] 0 0
Netherlands
State/province [92] 0 0
Noord Holland
Country [93] 0 0
Netherlands
State/province [93] 0 0
The Netherlands
Country [94] 0 0
Netherlands
State/province [94] 0 0
's-Hertogenbosch
Country [95] 0 0
Netherlands
State/province [95] 0 0
Alkmaar
Country [96] 0 0
Netherlands
State/province [96] 0 0
Amsterdam
Country [97] 0 0
Netherlands
State/province [97] 0 0
Eindhoven
Country [98] 0 0
Netherlands
State/province [98] 0 0
Leeuwarden
Country [99] 0 0
Netherlands
State/province [99] 0 0
Rotterdam
Country [100] 0 0
New Zealand
State/province [100] 0 0
NZ
Country [101] 0 0
New Zealand
State/province [101] 0 0
Christchurch
Country [102] 0 0
Poland
State/province [102] 0 0
Bydgoszcz
Country [103] 0 0
Poland
State/province [103] 0 0
Krakow
Country [104] 0 0
Poland
State/province [104] 0 0
Poznan
Country [105] 0 0
Poland
State/province [105] 0 0
Warszawa
Country [106] 0 0
Portugal
State/province [106] 0 0
Amadora
Country [107] 0 0
Portugal
State/province [107] 0 0
Coimbra
Country [108] 0 0
Portugal
State/province [108] 0 0
Lisboa
Country [109] 0 0
Serbia
State/province [109] 0 0
Belgrade
Country [110] 0 0
Serbia
State/province [110] 0 0
Kragujevac
Country [111] 0 0
Serbia
State/province [111] 0 0
Novi Sad
Country [112] 0 0
Serbia
State/province [112] 0 0
Sremska Kamenica
Country [113] 0 0
Slovakia
State/province [113] 0 0
Bratislava
Country [114] 0 0
Slovakia
State/province [114] 0 0
Michalovce
Country [115] 0 0
Slovakia
State/province [115] 0 0
Rimavska Sobota
Country [116] 0 0
South Africa
State/province [116] 0 0
Gauteng
Country [117] 0 0
South Africa
State/province [117] 0 0
Kwa Zulu Natal
Country [118] 0 0
South Africa
State/province [118] 0 0
Western Cape
Country [119] 0 0
Spain
State/province [119] 0 0
Alicante
Country [120] 0 0
Spain
State/province [120] 0 0
Barcelona
Country [121] 0 0
Spain
State/province [121] 0 0
Caceres
Country [122] 0 0
Spain
State/province [122] 0 0
Islas Baleares
Country [123] 0 0
Spain
State/province [123] 0 0
Pais Vasco
Country [124] 0 0
Spain
State/province [124] 0 0
Vizcalla
Country [125] 0 0
Spain
State/province [125] 0 0
Burgos
Country [126] 0 0
Spain
State/province [126] 0 0
Madrid
Country [127] 0 0
Spain
State/province [127] 0 0
Murcia
Country [128] 0 0
Sweden
State/province [128] 0 0
Malmo
Country [129] 0 0
Sweden
State/province [129] 0 0
Uppsala
Country [130] 0 0
Switzerland
State/province [130] 0 0
BS
Country [131] 0 0
Switzerland
State/province [131] 0 0
GE
Country [132] 0 0
Switzerland
State/province [132] 0 0
VD
Country [133] 0 0
Switzerland
State/province [133] 0 0
Thonex-Geneva
Country [134] 0 0
United Kingdom
State/province [134] 0 0
Lancashire
Country [135] 0 0
United Kingdom
State/province [135] 0 0
Manchester
Country [136] 0 0
United Kingdom
State/province [136] 0 0
Bradford
Country [137] 0 0
United Kingdom
State/province [137] 0 0
Brighton
Country [138] 0 0
United Kingdom
State/province [138] 0 0
Glasgow
Country [139] 0 0
United Kingdom
State/province [139] 0 0
London
Country [140] 0 0
United Kingdom
State/province [140] 0 0
Newcastle upon Tyne
Country [141] 0 0
United Kingdom
State/province [141] 0 0
Northampton
Country [142] 0 0
United Kingdom
State/province [142] 0 0
Penarth
Country [143] 0 0
United Kingdom
State/province [143] 0 0
Sheffield
Country [144] 0 0
United Kingdom
State/province [144] 0 0
Swindon

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT00676143